Sonnet BioTherapeutics (SONN) News Today $6.18 -1.61 (-20.67%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$6.17 -0.01 (-0.23%) As of 07/18/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SONN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Solana-based treasury model goes global as DeFi Development launches franchiseJuly 17 at 11:36 AM | msn.comWLFI tokens to become tradable after World Liberty holders’ voteJuly 17 at 6:36 AM | msn.comSonnet BioTherapeutics Stock Jumps 82% After Deal With Rorschach I: Retail Stays ExuberantJuly 15, 2025 | msn.comSonnet BioTherapeutics Shares Climb After Plan to Transfer Into Public Crypto Treasury Co.July 14, 2025 | marketwatch.comHyperliquid Price Forecast: HYPE eyes gains following Sonnet BioTherapeutics' rebrandJuly 14, 2025 | fxstreet.comHYPE coin price up 200%, Sonnet BioTherapeutics merges into Hyperliquid StrategiesJuly 14, 2025 | msn.comMassive deal sends biotech stock rallying 367%July 14, 2025 | msn.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sonnet BioTherapeutics, Inc. (NASDAQ: SONN)July 14, 2025 | globenewswire.comWhy Is Sonnet BioTherapeutics Stock Trading Higher On Monday?July 14, 2025 | benzinga.comSONN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Sonnet BioTherapeutics, Inc. Is Fair to ShareholdersJuly 14, 2025 | businesswire.comSonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve StrategyJuly 14, 2025 | globenewswire.comSonnet BioTherapeutics Completes $2 Million Convertible Notes SaleJuly 2, 2025 | tipranks.comsonnet biotherapeutics receives nasdaq delisting noticeJune 4, 2025 | investing.comSonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development SummitMay 1, 2025 | globenewswire.comSonnet Releases Virtual Investor "What This Means" SegmentApril 16, 2025 | globenewswire.comSonnet BioTherapeutics reports positive results from ovarian cancer therapy trialApril 7, 2025 | msn.comSonnet BioTherapeutics Reports Positive Phase 1b/2a Data For SON-1010April 6, 2025 | nasdaq.comSonnet BioTherapeutics advances in cancer trialApril 6, 2025 | uk.investing.comSonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at ...April 6, 2025 | seekingalpha.comSonnet Biotherapeutics Holdings Inc trading halted, news pendingApril 4, 2025 | markets.businessinsider.comSonnet says SON-1010 demonstrates ‘strong safety profile’ in atezolizumab comboApril 4, 2025 | markets.businessinsider.comSonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest DoseApril 4, 2025 | globenewswire.comSonnet BioTherapeutics appoints interim CEO and new presidentApril 3, 2025 | investing.comSonnet BioTherapeutics Names Raghu Rao Interim CEO As Founder PassesApril 3, 2025 | nasdaq.comPilot Killed In NJ Crash Was CEO Of Cancer-Focused Biotech CompanyApril 3, 2025 | msn.comPilot Killed In Franklin Twp Plane Crash Was CEO Of Cancer-Focused Biotech CompanyApril 2, 2025 | msn.comSonnet BioTherapeutics announces passing of founder, CEO Pankaj MohanApril 2, 2025 | markets.businessinsider.comSonnet Announces Release of Corporate Update VideoApril 1, 2025 | globenewswire.comPilot killed in N.J. plane crash was biotech company founder, CEOApril 1, 2025 | nj.comNSonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.April 1, 2025 | globenewswire.comSonnet BioTherapeutics completes first safety review of SON-1010March 27, 2025 | markets.businessinsider.comSonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain SarcomasMarch 26, 2025 | globenewswire.comSonnet BioTherapeutics receives notice of allowance for U.S. patent for IL-18March 20, 2025 | markets.businessinsider.comSonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant ProteinMarch 19, 2025 | globenewswire.comVirtual Investor Releases Next Wave of "Top 5 for '25" On-Demand VideosMarch 11, 2025 | markets.businessinsider.comSonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand ConferenceMarch 11, 2025 | globenewswire.comSonnet BioTherapeutics presents data on SON-1010February 26, 2025 | markets.businessinsider.comSonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid TumorsFebruary 26, 2025 | globenewswire.comSonnet announces ADC platform available for drug discovery partnershipsFebruary 19, 2025 | markets.businessinsider.comSonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug CandidatesFebruary 19, 2025 | globenewswire.comSonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO ConferenceFebruary 18, 2025 | globenewswire.comSonnet BioTherapeutics appoints McAndrew as Chief Business OfficerFebruary 13, 2025 | markets.businessinsider.comSonnet BioTherapeutics reports Q1 EPS ($1.56) vs ($2.46) last yearFebruary 13, 2025 | markets.businessinsider.comSonnet BioTherapeutics appoints new chief business officerFebruary 13, 2025 | msn.comSonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business OfficerFebruary 13, 2025 | globenewswire.comSonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings UpdateFebruary 13, 2025 | globenewswire.comSonnet BioTherapeutics further expands global IP portfolioJanuary 30, 2025 | markets.businessinsider.comSonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform TechnologyJanuary 28, 2025 | globenewswire.comSonnet BioTherapeutics files to sell 2M shares of common stock for holdersJanuary 23, 2025 | markets.businessinsider.comSonnet BioTherapeutics to expand trial of SON-1010 with trabectedin for solid tumoursJanuary 23, 2025 | msn.com Get Sonnet BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter. Email Address SONN Media Mentions By Week SONN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SONN News Sentiment▼0.370.59▲Average Medical News Sentiment SONN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SONN Articles This Week▼161▲SONN Articles Average Week Get Sonnet BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HilleVax News Today TScan Therapeutics News Today Cassava Sciences News Today Anixa Biosciences News Today Corbus Pharmaceuticals News Today Coya Therapeutics News Today TuHURA Biosciences News Today Contineum Therapeutics News Today Zentalis Pharmaceuticals News Today MacroGenics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SONN) was last updated on 7/20/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the sam...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonnet BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
